Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models

Cancer Prevention Research

Volumn 4, Issue 6, 2011, Pages 818-828

  Dragnev, Konstantin H ^a   Ma, Tian ^a   Cyrus, Jobin ^c   Galimberti, Fabrizio ^a   Memoli, Vincent ^a   Busch, Alexander M ^a   Tsongalis, Gregory J ^a   Seltzer, Marc ^a   Johnstone, David ^a,b   Erkmen, Cherie P ^a,b   Nugent, William ^a,b   Rigas, James R ^a   Liu, Xi ^a   Freemantle, Sarah J ^a   Kurie, Jonathan M ^d   Waxman, Samuel ^e   Dmitrovsky, Ethan ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c DARTMOUTH COLLEGE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEXAROTENE; CYCLIN D1; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FENOFIBRATE; K RAS PROTEIN; KI 67 ANTIGEN; PROTEIN P53;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER PREVENTION; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; CONFUSION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EOSINOPHILIA; FEMALE; HEMOPTYSIS; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPONATREMIA; INFLAMMATION; LEUKOPENIA; LIOTHYRONINE BLOOD LEVEL; LUNG BIOPSY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NECROSIS; NONHUMAN; ORAL BIOPSY; OVERALL SURVIVAL; PLEURA EFFUSION; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SIDE EFFECT; THYROXINE BLOOD LEVEL; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN D1; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; MOUTH MUCOSA; MUTATION; NECROSIS; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SALVAGE THERAPY; SURVIVAL RATE; TETRAHYDRONAPHTHALENES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 79957860099     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0376     Document Type: Article

References (50)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Dragnev KH, Stover D, Dmitrovsky E. Lung cancer prevention: the guidelines. Chest 2003;123:60S-71S.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70. (Pubitemid 30046295)
4. Sherr CJ. Cell cycle control and cancer. Harvey Lect 2000;96: 73-92.
5. Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS. Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res 1999;59:2470-6. (Pubitemid 29242299)
6. Betticher DC, Heighway J, Hasleton PS, Altermatt HJ, Ryder WD, Cerny T, et al. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 1996;73:294-300. (Pubitemid 26047506)
7. Betticher DC, White GR, Vonlanthen S, Liu X, Kappeler A, Altermatt HJ, et al. G1 control gene status is frequently altered in resectable non-small cell lung cancer. Int J Cancer 1997;74:556-62. (Pubitemid 27486516)
8. Ratschiller D, Heighway J, Gugger M, Kappeler A, Pirnia F, Schmid RA, et al. Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol 2003;21:2085-93. (Pubitemid 46606356)
9. Freemantle SJ, Liu X, Feng Q, Galimberti F, Blumen S, Sekula D, et al. Cyclin degradation for cancer therapy and chemoprevention. J Cell Biochem 2007;102:869-77. (Pubitemid 350036927)
10. Rusch V, Mendelsohn J, Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev 1996;7:133-41. (Pubitemid 27198072)
11. Rusch V, Klimstra D, Linkov I, Dmitrovsky E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res 1995;55:1365-72.
12. Sah JF, Eckert RL, Chandraratna RAS, Rorke EA. Retinoids suppress epidermal growth factor-associated cell proliferation by inhibiting epidermal growth factor receptor-dependent ERK1/2 activation. J Biol Chem 2002;277:9728-35. (Pubitemid 34968074)
13. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002;62:3351-5. (Pubitemid 34651376)
14. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001;3:802-8. (Pubitemid 32842685)
15. Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, Wentzel AL, et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ 2002;13:355-62.
16. Buerger C, Nagel-Wolfrum K, Kunz C, Wittig I, Butz K, Hoppe-Seyler F, et al. Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. J Biol Chem 2003;278:37610-21. (Pubitemid 37175284)
17. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003;22:4150-65. (Pubitemid 36876236)
18. Park OK, Schaefer TS, Nathans D. In vitro activation of Stat3 by epidermal growth factor receptor kinase. Proc Natl Acad Sci U S A 1996;93:13704-8.
19. Petty WJ, Dragnev KH, Memoli VA, Ma Y, Desai NB, Biddle A, et al. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res 2004;10: 7547-54. (Pubitemid 39557516)
20. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32. (Pubitemid 41058344)
21. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9:962-72.
22. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl Med 2004;350:2129-39. (Pubitemid 38637993)
23. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500. (Pubitemid 38720929)
24. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
25. Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003;22: 7305-15. (Pubitemid 37487162)
26. Dragnev KH, Pitha-Rowe I, Ma Y, Petty WJ, Sekula D, Murphy B, et al. Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clin Cancer Res 2004;10:2570-7. (Pubitemid 38445720)
27. Langenfeld J, Kiyokawa H, Sekula D, Boyle J, Dmitrovsky E. Post-translational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci U S A 1997;94:12070-4. (Pubitemid 27467844)
28. Lonardo F, Dragnev KH, Freemantle SJ, Ma Y, Memoli N, Sekula D, et al. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 2002;8:54-60. (Pubitemid 34101459)
29. Boyle JO, Langenfeld J, Lonardo F, Sekula D, Reczek P, Rusch V, et al. Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells. J Natl Cancer Inst 1999;91:373-9. (Pubitemid 29102338)
30. Dragnev KH, Petty WJ, Shah SJ, Lewis LD, Black CC, Memoli V, et al. A proof-of-principle clinical trial of bexarotene in patients with nonsmall cell lung cancer. Clin Cancer Res 2007;13:1794-800. (Pubitemid 46952948)
31. Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, et al. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res 2006;66:11389-98. (Pubitemid 46009970)
32. Rubin Grandis J, Zeng Q, Tweardy DJ. Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines. Nat Med 1996;2:237-40. (Pubitemid 26054987)
33. Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, et al. Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol 2005;23:8757-64. (Pubitemid 46211521)
34. Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, et al. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A 2007;104:4089-94. (Pubitemid 47181583)
35. Freemantle SJ, Dmitrovsky E. Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy and prevention. Cancer Prev Res 2010;3:1513-8.
36. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, et al. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 2009;23:2140-51.
37. Lìevre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9. (Pubitemid 351171687)
38. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005;7:396-403. (Pubitemid 41149655)
39. Clopper C, Pearson ES, Lee JJ, Blumenschein GR, Tsao A, et al. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-13.
40. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, et al. The BATTLE Trial: personalizing therapy for lung cancer. Cancer Discovery 2011;1:44-53.
41. Khuri FR, Rigas JR, Figlin RA, Gralla RJ, Shin DM, Munden R, et al. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2001;19:2626-37. (Pubitemid 32441367)
42. Blumenschein GR, Khuri FR, von Pawel J, Gatzemeier U, Miller WH, Jotte RM, et al. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol 2008;26:1879-85.
43. Edelman MJ. Second-line chemotherapy and beyond for non-small-cell lung cancer. Clin Adv Hematol Oncol 2004;2:373-8.
44. Massarelli E, Andre F, Liu DD, Lee JJ, Wolf M, Fandi A, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003;39:55-61. (Pubitemid 36020295)
45. Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2006;12: 5659-67. (Pubitemid 44629592)
46. Sunaga N, Oriuchi N, Kaira K, Yanagitani N, Tomizawa Y, Hisada T, et al. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 2008;59:203-10. (Pubitemid 351173409)
47. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
48. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007;13:2890-6. (Pubitemid 46849563)
49. Galimberti F, Thompson SL, Liu X, Li H, Memoli V, Green SR, et al. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clin Cancer Res 2010;16: 109-20.
50. Liby K, Black CC, Royce DB, Williams CR, Risingsong R, Yore MM, et al. The rexinoid LG100268 and the synthetic triterpenoid CDDOmethyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Mol Cancer Ther 2008;7:1251-7.